George Gavriilidis

Dr. George Gavriilidis

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2024 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
GGGeorge Gavriilidis
George Gavriilidis
VVVasileios Vasileiou
Vasileios Vasileiou
AOAspasia Orfanou
Aspasia Orfanou
NINaveed Ishaque
Naveed Ishaque
Fotis PsomopoulosFotis Psomopoulos
Fotis Psomopoulos
Recent advances in single-cell omics technology have transformed the landscape of cellular and molecular research, enriching the scope and intricacy of cellular characterisation. Perturbation modelling seeks to comprehensively grasp the effects of external influences like disease onset or molecular knock-outs or external stimulants on cellular physiology, specifically on transcription factors, signal transducers, biological pathways, and dynamic cell states. Machine and deep learning tools transform complex perturbational phenomena in algorithmically tractable tasks to formulate predictions based on various types of single-cell datasets. However, the recent surge in tools and datasets makes it challenging for experimental biologists and computational scientists to keep track of the recent advances in this rapidly expanding filed of single-cell modelling. Here, we recapitulate the main objectives of perturbation modelling and summarise novel single-cell perturbation technologies based on genetic manipulation like CRISPR or compounds, spanning across omic modalities. We then concisely review a burgeoning group of computational methods extending from classical statistical inference methodologies to various machine and deep learning architectures like shallow models or autoencoders, to biologically informed approaches based on gene regulatory networks, and to combinatorial efforts reminiscent of ensemble learning. We also discuss the rising trend of large foundational models in single-cell perturbation modelling inspired by large language models. Lastly, we critically assess the challenges that underline single-cell perturbation modelling while pointing towards relevant future perspectives like perturbation atlases, multi-omics and spatial datasets, causal machine learning for interpretability, multi-task learning for performance and explainability as well as prospects for solving interoperability and benchmarking pitfalls.

21 October 2021 in Drug Safety
Verified
Journal Article
Open access
PDF file
GGGeorge Gavriilidis
George Gavriilidis
VDVlasios K. Dimitriadis
Vlasios K. Dimitriadis
MJMarie-Christine Jaulent
Marie-Christine Jaulent
PNPantelis Natsiavas
Pantelis Natsiavas
Introduction Information technology (IT) plays an important role in the healthcare landscape via the increasing digitization of medical data and the use of modern computational paradigms such as machine learning (ML) and knowledge graphs (KGs). These ‘intelligent’ technical paradigms provide a new digital ‘toolkit’ supporting drug safety and healthcare processes, including ‘active pharmacovigilance’. While these technical paradigms are promising, intelligent systems (ISs) are not yet widely adopted by pharmacovigilance (PV) stakeholders, namely the pharma industry, academia/research community, drug safety monitoring organizations, regulatory authorities, and healthcare institutions. The limitations obscuring the integration of ISs into PV activities are multifaceted, involving technical, legal and medical hurdles, and thus require further elucidation. Objective We dissect the abovementioned limitations by describing the lessons learned during the design and implementation of the PVClinical platform, a web platform aiming to support the investigation of potential adverse drug reactions (ADRs), emphasizing the use of knowledge engineering (KE) as its main technical paradigm. Results To this end, we elaborate on the related ‘business processes’ (i.e. operational processes) and ‘user goals’ identified as part of the PVClinical platform design process based on Design Thinking principles. We also elaborate on key challenges restricting the adoption of such ISs and their integration in the clinical setting and beyond. Conclusions We highlight the fact that beyond providing analytics and useful statistics to the end user, ‘actionability’ has emerged as the operational priority identified through the whole process. Furthermore, we focus on the needs for valid, reproducible, explainable and human-interpretable results, stressing the need to emphasize on usability.

21 January 2025 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
ASAthanasios Sachinidis
Athanasios Sachinidis
MTMaria Trachana
Maria Trachana
ATAnna Taparkou
Anna Taparkou
GGGeorge Gavriilidis
George Gavriilidis
VVVasileios Vasileiou
Vasileios Vasileiou
AGAlexandros Garyfallos
Alexandros Garyfallos
Objective: To investigate whether T-bet+ B cells, as well as age-associated B cells/ABCs (CD19 + CD21-CD11c + T-bet+) and double-negative B cells/DN (CD19 + IgD-CD27- CXCR5-T-bet+), serve as prognostic and/or therapeutic tools for systemic lupus erythematosus (SLE) in humans. Methods: Flow cytometry was used for enumerating T-bet+ B cells and ABCs/DN subsets, found in the peripheral blood of 10 healthy donors and 22 active SLE patients. Whole blood assay cultures, combined with in vitro pharmacological treatments, were performed to evaluate the effects of hydroxychloroquine, anifrolumab, and fasudil (a ROCK kinase inhibitor) on T-bet+ B cells’ percentage. Moreover, previously published single-cell RNA sequencing (scRNA-seq) data were used in a meta-analysis to allow characterization of genes and pathways associated with the biology of T-bet in B cells. Results: T-bet+ B cells displayed an expansion in SLE patients [1.47 (1.9–0.7) vs 10.85 (37.4–3.6)]. Similarly, both ABCs and DN were found to be expanded. Interestingly, percentages of T-bet+ B cells positively correlated with patients’ SLEDAI scores (rs = 0.55, P = 0.007). Cell culture experiments conducted revealed that all three agents tested can deplete T-bet + B cells (without affecting the cell viability of lymphocytes, T cells, and B cells). According to bioinformatics analyses, T-bet is highly expressed in two B-cell clusters with pathogenic characteristics for SLE (designated as atypical memory B cells and activated naïve B cells). These clusters can be targeted for therapeutic interventions. Conclusions: T-bet+ B cells can serve as a putative prognostic biomarker of lupus severity. Circumstantial data suggest that these cells may promote disease pathogenesis and may represent a novel therapeutic target.

1 March 2020 in Haematologica
Verified
Journal Article
Open access
PDF file
GGGeorge Gavriilidis
George Gavriilidis
SNStavroula Ntoufa
Stavroula Ntoufa
NPNikos Papakonstantinou
Nikos Papakonstantinou
KKKonstantia Kotta
Konstantia Kotta
TKTriantafyllia Koletsa
Triantafyllia Koletsa
KSKostas Stamatopoulos
Kostas Stamatopoulos
The inflammatory cytokine Stem Cell Factor (SCF, ligand of c-kit receptor) has been implicated as a pro-oncogenic driver and an adverse prognosticator in several human cancers. Increased SCF levels have recently been reported in a small series of patients with chronic lymphocytic leukemia (CLL), however its precise role in CLL pathophysiology remains elusive. In this study, CLL cells were found to predominantly express the membrane isoform of SCF that is known to elicit a more robust activation of the c-kit receptor. SCF was significantly overexpressed in CLL cells compared to healthy tonsillar B cells whilst it correlated with adverse-prognostic biomarkers, shorter time-to-first treatment and shorter overall survival. Activation of immune receptors and long-term cell-cell interactions with the mesenchymal stroma led to an elevation of SCF primarily in adverse-prognostic CLL cases. On the contrary, suppression of oxidative stress and the BTK inhibitor Ibrutinib negated SCF levels. Interestingly, SCF significantly correlated with mitochondrial dynamics and HIF-1α which have previously been linked with clinical aggressiveness in CLL. SCF was able to elicit direct biological effects in CLL cells affecting redox homeostasis and cell proliferation. Overall, the aberrantly expressed SCF in CLL cells emerges as a key response regulator to microenvironmental stimuli whilst correlating with poor prognosis. On these grounds, specific targeting of this inflammatory molecule could serve as a novel therapeutic approach in CLL.

30 October 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
LPLefkothea Papadopoulou
Lefkothea Papadopoulou
AIAlexandra Ingendoh-Tsakmakidis
Alexandra Ingendoh-Tsakmakidis
CMChristina N. Mpoutoureli
Christina N. Mpoutoureli
LTLamprini D. Tzikalou
Lamprini D. Tzikalou
ESEfthymia D. Spyridou
Efthymia D. Spyridou
ATAsterios Tsiftsoglou
Asterios Tsiftsoglou

8 February 2025 in Bioinformatics
Verified
Journal Article
Open access
GGGeorge Gavriilidis
George Gavriilidis
VVVasileios Vasileiou
Vasileios Vasileiou
SDStella Dimitsaki
Stella Dimitsaki
GKGeorgios Karakatsoulis
Georgios Karakatsoulis
AGAntonis Giannakakis
Antonis Giannakakis
Fotis PsomopoulosFotis Psomopoulos
Fotis Psomopoulos
Motivation: Computational analyses of bulk and single-cell omics provide translational insights into complex diseases, such as COVID-19, by revealing molecules, cellular phenotypes, and signalling patterns that contribute to unfavourable clinical outcomes. Current in silico approaches dovetail differential abundance, biostatistics, and machine learning, but often overlook non-linear proteomic dynamics, like post-translational modifications, and provide limited biological interpretability beyond feature ranking. Results: We introduce APNet, a novel computational pipeline that combines differential activity analysis based on SJARACNe co-expression networks with PASNet, a biologically-informed sparse deep learning model, to perform explainable predictions for COVID-19 severity. The APNet driver-pathway network ingests SJARACNe co-regulation and classification weights to aid result interpretation and hypothesis generation. APNet outperforms alternative models in patient classification across three COVID-19 proteomic datasets, identifying predictive drivers and pathways, including some confirmed in single-cell omics and highlighting under-explored biomarker circuitries in COVID-19. Availability and Implementation: APNet’s R, Python scripts and Cytoscape methodologies are available at https://github.com/BiodataAnalysisGroup/APNet. Supplementary Information: Supplementary information can be accessed in Zenodo (10.5281/zenodo.14680520).